Antibiotic resistance on the move: the role of international travel

Dr. med. Esther Künzli

MD, PD

As people cross borders, they can unknowingly carry resistant bacteria with them. Understanding this connection is essential to developing effective strategies that protect public health worldwide.


Modern medicine as we know it would not be possible without effective antibiotics. Following Alexander Fleming’s discovery of penicillin in 1928 and its introduction as a treatment in the 1940s, infections that had previously often been fatal became treatable.

Antibiotic resistance as a One Health challenge

Today, however, antibiotic resistance is threatening these advances. The World Health Organization considers antimicrobial resistance one of the leading global public health and development threats. In 2021, an estimated 4.71 million deaths were associated with bacterial antimicrobial resistance, including 1.14 million deaths directly attributable to it.1

The emergence and spread of resistant bacteria is a quintessential One Health challenge, connecting human and animal health with the environment. While the misuse and overuse of antibiotics are among the main drivers of antibiotic resistance, other factors, including sanitary infrastructure and hygiene, overall health expenditure and governance, also influence its prevalence. Across borders, resistant bacteria spread through patient transfers, medical tourism and international travel.

International travellers can spread resistant bacteria

Over the past 20 years, awareness has grown that international travellers can contribute to the global spread of multidrug-resistant bacteria, especially extended-spectrum beta-lactamase-producing Escherichia coli, or ESBL-producing E. coli. Travellers can carry these bacteria in their gastrointestinal tract.

In studies we have conducted, we found this asymptomatic carriage (or ‘colonisation’) in up to three-quarters of travellers, depending on the region visited.2 In most cases, colonisation is asymptomatic, and the bacteria disappear after some time. However, in some people, they can cause infections, such as urinary tract infections. These infections may then require different antibiotics from those commonly used to treat infections acquired at home.

This issue is becoming increasingly relevant as international travel continues to rise. In 2025, international tourist arrivals reached a record 1.52 billion worldwide, exceeding pre-pandemic levels.3

we found this asymptomatic carriage (or ‘colonisation’) in up to three-quarters of travellers, depending on the region visited

No single intervention beats antibiotic resistance

Antibiotic resistance is a complex and multifaceted global challenge. Preventing infections, using existing antibiotics responsibly, improving sanitation and surveillance and developing new treatments are all essential.

Addressing these challenges requires coordinated action across countries and sectors. Only by limiting both the emergence and spread of resistance can we preserve effective antibiotics as one of the foundations of modern medicine.

[1] GBD 2021 Antimicrobial Resistance Collaborators. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199–1226. https://doi.org/10.1016/S0140-6736(24)01867-1
[2]  Pires, J., et al. (2019). Gut microbiota dynamics in travellers returning from India colonized with extended-spectrum cephalosporin-resistant Enterobacteriaceae: A longitudinal study. Travel Medicine and Infectious Disease, 27, 72–80. https://doi.org/10.1016/j.tmaid.2018.10.012
[3] UN Tourism. (2026). International tourist arrivals up 4% in 2025 reflecting strong travel demand around the world. tinyurl.com/3bck2hv3

More from AMR & Infectious Diseases